LakeShore Biopharma Announces Financial Results for Fiscal Year 2024

Provided By PR Newswire

Last update: Aug 15, 2024

Gross margin increased to 79.5%; product pipeline continues to advance

Company anticipates double-digit year-over-year revenue growth and bottom line breakeven for Fiscal Year 2025